联合核基质蛋白22与膀胱肿瘤抗原监测膀胱肿瘤复发的意义

Urine nuclear matrix protein 22 and bladder tumor antigen test in the screening of bladder tumor recurrence

目的 探寻无创 快速 便捷的监测膀胱肿瘤复发的方法。 方法 对 90例TURBt术后患者 ,采用标准ELISA法检测尿核基质蛋白 2 2 (NMP 2 2 )值 ,同时采用单抗免疫分析法测定膀胱肿瘤抗原 (BTAstat)、膀胱镜检及病理检测有无肿瘤复发。 结果 与膀胱镜检及活检结果相比较 ,尿NMP 2 2检测可发现 77% ( 3 3 /4 3 )复发病例 ,尿BTAstat检测可发现 67% ( 2 9/4 3 )复发病例。 2项检测综合分析 ,检测准确率升至 93 % ( 40 /4 3 )。 结论 尿NMP 2 2检测为快速、高效、便捷的监测膀胱肿瘤复发的方法 ,联合BTAStat检测可提高准确率 。

Objective To evaluate the quantitative determination of urine nuclear matrix protein 22 (NMP-22) and bladder tumor antigen (BTA) in the screening of bladder tumor recurrence. Methods 90 patients who had undergone TURBT were recruited in this study.Standard ELISA test was used to determine the quantity of NMP-22 in urine and urine BTA stat test was also performed.the findings were analyed with reference to the cystoscopic and pathological results. Results In comparison with the results of cystoscopy,urine NMP-22 test might denote 77% (32/43) recurrence of bladder cancer and this positive rate would increase to 93% (40/43) with the combined use of urine NMP-22 and BTA test. Conclusions Examination of NMP-22 in urine is a rapid and effective means of detecting the recurrence of bladder cancer.With the combined use of BTA test,urine NMP-22 determination might be a useful non-invasive method in screening the recurrence of bladder cancer,and the conventional invasive cystoscopy might be avoided.